User:MBC 01/Center for Translational Molecular Medicine
 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
Center for Translational Molecular Medicine ...
| Established | 2006 |
|---|---|
| Focus | Translating science into better healthcare |
| Chair of the Supervisory Board | Frank de Grave |
| Budget | €302.7 million |
| Location | High Tech Campus, Eindhoven, The Netherlands , The Netherlands |
| Website | www |
The Center for Translational Molecular Medicine (CTMM) is a Dutch research organization that focuses on the development of medical technologies that enable the early diagnosis and personalized treatment of major diseases that cause mortality and diminished quality of life. The areas of disease that its research projects address are cancer, cardiovascular, neurodegenerative, infectious and autoimmune diseases.[1] Founded in 2006 with its headquarters on the High Tech Campus Eindhoven, the CTMM is one of the Netherlands’ Technological Top Institutes (TTIs) and is funded via a public-private partnership between the Dutch government, academic institutions and industrial partners (most of which are Netherlands based). As at January 2012, the CTMM had a total of 112 partners, comprising large industrial companies, small and medium enterprises (SMEs) and academic institutes, including all eight Dutch university medical centers and two technical universities (Eindhoven University of Technology and Delft University of Technology).[2]
The CTMM provides the legal, accounting and project coordination services - for example, calls for proposals and project selection, approval, monitoring and review - to fund eighteen 5-year and three 4-year translational molecular medicine research projects and one IT infrastructure project in the Netherlands.[3] As at January 2012, the total funding allocated to these projects was Euro 302.7 million. The CTMM also provides education and training programs for its members.[3]
Research Projects[edit]
As at January 2012, the CTMM had 22 ongoing research projects (21 translational molecular medicine research projects and one IT infrastructure project), eighteen of which will run for 5 years and four of which will run for 4 years.[1][4]
Grouped by disease area the projects are:[1]
| Disease Area | Project Name/Description | Acronym |
|---|---|---|
| Cancer | Personalized chemo-radiation of lung and head and neck cancer | Airforce |
| BioChip diagnostic tests for acute leukemia and multiple myeloma | BioChip | |
| Neoadjuvant drug treatment for breast cancer response prediction and response monitoring | Breast Care | |
| Cancer Vaccine Tracking | - | |
| Decrease colorectal cancer death | DeCode | |
| Application of MRI-guided High Intensity Focused Ultrasound (HIFU) to improve cancer chemotherapy with temperature-sensitive targeted nanomedicines | HIFU-CHEM | |
| Mammary carcinoma molecular imaging for diagnosis and therapeutics | MamMoth | |
| Intra-operative multi-spectral imaging systems for radical tumor resection | Musis | |
| Prostate cancer molecular medicine | PCMM | |
| Non-invasive treatment of cancer by MRI-guided high-intensity focused ultrasound ablation: volumetric thermal ablation | Volta | |
| Cardiovascular Disease | Circulating Cells: The natural sensors of plaque and patient destabilization | Circulating Cells |
| Biomarkers to predict cardiac failure, arrhythmias and success of treatment | Cohfar | |
| Developing multiple diagnostic technologies to enable the early sensitive detection of neovascularization, and novel tools to stratify an individual patient’s risk of cardiovascular disease | Eminence | |
| Innovative coagulation diagnostics | Incoag | |
| Assessment of plaque at risk by non-invasive (molecular) imaging and modeling | Parisk | |
| Biomarkers for the prediction and early diagnosis of diabetes and diabetes-related cardiovascular complications | Predicct | |
| Translational initiative on unique and novel strategies for the management of patients with heart failure | Triumph | |
| Neurodegenerative Disease | In-vivo molecular diagnostics in Alzheimer's disease | Learn |
| Infection and Immunity | Design and use of enhanced T cell antigens and T cell detection technology for human disease | AmpVacs |
| Molecular diagnosis and risk stratification of sepsis | Mars | |
| Development of tools and prediction rules to time and select therapy in the treatment of pre-clinical, early and established rheumatoid arthritis: creating enhanced remedy | Tracer |
The 22nd project is called TraIT (Translational research IT) and aims to develop a sustainable and scalable IT infrastructure in the Netherlands based on proven technology.[5] TraIT will allow researchers in distributed research centers to combine and jointly analyze their data to develop more personalized healthcare in disease areas such as cancer and cardiovascular disease.
Every project is subject to a Midterm Review by the International Scientific Advisory Board, which critically analyzes the extent to which the project has progressed and helps CTMM to identify practical measures to increase commitment, resourcing and efforts during the second half of the project.
Funding[edit]
How CTMM Obtains Funding[edit]
In 2007 and 2008, the Dutch government committed Euro 150 million to the newly formed CTMM from the government’s FES fund (Fonds Economische Structuurversterking), which it created using revenues from its Slochteren natural gas field in the North of the Netherlands.[citation needed] The public-private partnership agreement under which CTMM operates requires that this Euro 150 million from the Dutch government is matched by funding from CTMM’s industrial and academic partners, giving the CTMM a total budget of Euro 300 million to spend on translational research.[citation needed] Some projects were awarded additional funding from Dutch charitable organizations, including the Dutch Heart Foundation, Diabetes Research Foundation, Kidney Foundation, Arthritis Foundation and Cancer Society.[1][5]
How CTMM Allocates Funding[edit]
Project proposals, which are evaluated by CTMM’s independent International Scientific Advisory Committee and approved by CTMM’s Supervisory Board, bring together consortia of industrial and academic partners. The consortium partners collectively agree to match the government funding allocated to the project, in an even split between the industrial and academic groups.[citation needed] Hence for each CTMM project, 50% of the project funding comes from the Dutch government, 25% from the project’s industrial partners and 25% from its academic partners.[3] Depending on their resources, partners can either contribute funding in cash or in-kind (i.e. in the form of goods or services). The funding for each project is spread over the duration of the project and is administered by CTMM.
See also[edit]
References[edit]
- ^ a b c d
CTMM. "CTMM Annual Report 2010". CTMM. Retrieved March 25, 2012.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help) - ^
CTMM. "Partners in the CTMM consortium". CTMM. Retrieved March 25, 2012.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help) - ^ a b c
CTMM. Engels "About CTMM". CTMM. Retrieved March 25, 2012.
{{cite web}}: Check|url=value (help); Cite has empty unknown parameter:|coauthors=(help) - ^
CTMM. "CTMM Projects - general information". CTMM. Retrieved March 25, 2012.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help) - ^ a b
"Sixteen million Euro to accelerate the translation of highly promising medical research into clinical care" (Press release). CTMM. October 3, 2011.
{{cite press release}}: line feed character in|title=at position 94 (help)
External links[edit]